J07AL02 • polysaccharide conjugate pneumococcal vaccine • Antiinfectives for systemic use | Bacterial vaccines | Pneumococcal vaccines
The pneumococcal conjugate vaccine (PCV13) is used to prevent infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and otitis media. The vaccine contains capsular polysaccharides from 13 different serotypes of the bacterium, linked to a carrier protein, which stimulates a stronger and longer-lasting immune response.
The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for children, adults, and individuals at increased risk of pneumococcal infections.
Common side effects include pain at the injection site, mild fever, irritability, and fatigue. In rare cases, severe allergic reactions may occur.
The pneumococcal conjugate vaccine is an essential measure for protecting against pneumococcal infections, particularly among young children and vulnerable individuals, helping to reduce the morbidity and mortality associated with these infections.
Substance: polysaccharide conjugate pneumococcal vaccine
Date of last drug list: 01-09-2016
Commercial code: W60168002
Pharmaceutical form: suspension for injection in pre-filled syringe
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).